Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
29 August 2024 - 2:00PM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced that Clay Siegall, PhD, President and
CEO of Immunome, will participate in a fireside chat at the Morgan
Stanley 22nd Annual Global Healthcare Conference on Wednesday,
September 4, 2024 at 5:35 P.M. Eastern Time.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company’s
website at www.immunome.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 30
days.
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed
to developing first-in-class and best-in-class targeted therapies
designed to improve outcomes for cancer patients. We are advancing
an innovative portfolio of therapeutics, drawing on leadership that
previously played key roles in the design, development and
commercialization of cutting-edge targeted cancer therapies,
including antibody-drug conjugates (ADCs). In addition to a
portfolio of discovery-stage ADCs, our pipeline includes AL102, a
gamma secretase inhibitor currently in a Phase 3 trial for
treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and
IM-3050, a FAP-targeted radioligand, both of which are the subject
of INDs expected to be submitted in the first quarter of 2025. For
more information, visit www.immunome.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240829122114/en/
Investor Contact Max Rosett Chief Financial Officer
investors@immunome.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Nov 2023 bis Nov 2024